These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11354294)

  • 1. The presence of superantigens and complex host responses in severe sepsis may need a broad therapeutic approach.
    Stegmayr BG
    Ther Apher; 2001 Apr; 5(2):111-4. PubMed ID: 11354294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superantigens and streptococcal toxic shock syndrome.
    Proft T; Sriskandan S; Yang L; Fraser JD
    Emerg Infect Dis; 2003 Oct; 9(10):1211-8. PubMed ID: 14609454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.
    Sriskandan S; Faulkner L; Hopkins P
    Int J Biochem Cell Biol; 2007; 39(1):12-9. PubMed ID: 17029999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual genetic variations directly effect polarization of cytokine responses to superantigens associated with streptococcal sepsis: implications for customized patient care.
    Nooh MM; Nookala S; Kansal R; Kotb M
    J Immunol; 2011 Mar; 186(5):3156-63. PubMed ID: 21282506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and function of streptococcal and staphylococcal superantigens in septic shock.
    Bannan J; Visvanathan K; Zabriskie JB
    Infect Dis Clin North Am; 1999 Jun; 13(2):387-96, ix. PubMed ID: 10340173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoadsorption therapy for sepsis syndromes.
    Kellum JA
    Crit Care Med; 2003 Jan; 31(1):323-4. PubMed ID: 12545045
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
    Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
    Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the mysteries of streptococci and their relations with the host.
    Ferrieri P; Horaud T
    Trends Microbiol; 1997 Jan; 5(1):5-7. PubMed ID: 9025228
    [No Abstract]   [Full Text] [Related]  

  • 9. The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis.
    Reglinski M; Sriskandan S
    Virulence; 2014 Jan; 5(1):127-36. PubMed ID: 24157731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
    Norrby-Teglund A; Low DE; McGeer A; Kotb M
    Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
    [No Abstract]   [Full Text] [Related]  

  • 11. Superantigens: microbial agents that corrupt immunity.
    Llewelyn M; Cohen J
    Lancet Infect Dis; 2002 Mar; 2(3):156-62. PubMed ID: 11944185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome.
    Sriskandan S; Moyes D; Cohen J
    Lancet; 1996 Nov; 348(9037):1315-6. PubMed ID: 8909404
    [No Abstract]   [Full Text] [Related]  

  • 13. The bacterial superantigen and superantigen-like proteins.
    Fraser JD; Proft T
    Immunol Rev; 2008 Oct; 225():226-43. PubMed ID: 18837785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gram-positive toxic shock syndromes.
    Lappin E; Ferguson AJ
    Lancet Infect Dis; 2009 May; 9(5):281-90. PubMed ID: 19393958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project.
    Watanabe-Ohnishi R; Low DE; McGeer A; Stevens DL; Schlievert PM; Newton D; Schwartz B; Kreiswirth B; Kotb M
    J Infect Dis; 1995 Jan; 171(1):74-84. PubMed ID: 7798684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen class II haplotypes that protect against or predispose to streptococcal toxic shock.
    Llewelyn M
    Clin Infect Dis; 2005 Nov; 41 Suppl 7():S445-8. PubMed ID: 16237645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis.
    Nooh MM; El-Gengehi N; Kansal R; David CS; Kotb M
    J Immunol; 2007 Mar; 178(5):3076-83. PubMed ID: 17312154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome.
    Thomas D; Perpoint T; Dauwalder O; Lina G; Floccard B; Richard JC; Bouvet A; Peyramond D; Allaouchiche B; Chidiac C; Vandenesch F; Etienne J; Ferry T
    Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):671-6. PubMed ID: 19020908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptococcal superantigens.
    Proft T; Fraser JD
    Chem Immunol Allergy; 2007; 93():1-23. PubMed ID: 17369697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Superantigens and toxic shock syndrome. A report of three cases treated with intravenous gammaglobulin].
    Vázquez García RE; Hernández Bautista V; Espinosa Padilla S
    Rev Alerg Mex; 2006; 53(5):183-8. PubMed ID: 17357565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.